Synthesis of cyclosporin analogs
AssigneeIsotechnika Inc.
InventorsSelvaraj A. Naicker, Randall W. Yatscoff, Robert T. Foster, Mark Abel, Seetharaman Jayaraman, Hans-Jurgen Mair, Jean-Michel Adam, Bruno Lohri
Life of this patent
Estimating the term…
Loading patent…
AssigneeIsotechnika Inc.
InventorsSelvaraj A. Naicker, Randall W. Yatscoff, Robert T. Foster, Mark Abel, Seetharaman Jayaraman, Hans-Jurgen Mair, Jean-Michel Adam, Bruno Lohri
Estimating the term…
The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISATX247, and derivatives thereof. ISATX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. Stereoselective pathways may utilize a Wittig reaction, or an organometallic reagent comprising inorganic elements such as boron, silicon, titanium, and lithium. The ratio of isomers in a mixture may range from about 10 to 90 percent by weight of the (E)-isomer to about 90 to 10 percent by weight of the (Z)-isomer, based on the total weight of the mixture.
A method of preparing an isomeric mixture of cyclosporin A analogs modified at the 1-amino acid residue, wherein the synthetic pathway comprises the steps of:
A method of preparing an isomeric mixture of cyclosporin A analogs modified at the 1-amino acid residue, wherein the synthetic pathway comprises the steps of:
A method of preparing an isomeric mixture of cyclosporin A analogs modified at the 1-amino acid residue, wherein the synthetic pathway comprises the steps of:
A method of producing an E-isomer enriched mixture of cyclosporin A analogs modified at the 1-amino acid residue, wherein the stereoselective synthesis of the E-isomer enriched material comprises the steps of:
A method of producing a Z-isomer enriched mixture of cyclosporin A analogs modified at the 1-amino acid residue, wherein the stereoselective synthesis of the Z-isomer enriched material comprises the steps of:
A method of producing an E-isomer enriched mixture of cyclosporin A analogs modified at the 1-amino acid residue, wherein the stereoselective synthesis of the E-isomer enriched material comprises the steps of:
A method of producing a Z-isomer enriched mixture of cyclosporin A analogs modified at the 1-amino acid residue, wherein the stereoselective synthesis of the Z-isomer enriched material comprises the steps of:
A mixture of (E) and (Z)-isomers prepared by a process comprising the steps of:
A composition comprising a triphenylphosphonium salt of acetyl-η-halocyclosporin A.
A composition comprising a β-trimethylsilyl alcohol derivative of cyclosporin A.
A method for the preparation of cyclosporin A aldehyde comprising the steps of:
A method for the preparation of cyclosporin A aldehyde comprising the steps of:
A method of preparing an isomeric mixture of cyclosporin A analogs modified at the 1-amino acid residue, wherein the synthetic pathway comprises the steps of:
A method for the stereoselective synthesis of the E-isomer of ISATX247 comprising the steps of:
A method for the stereoselective synthesis of the Z-isomer of ISATX247 comprising the steps of:
A method of preparing an isomeric mixture of cyclosporin A analogs modified at the 1-amino acid residue, the method comprising a synthetic pathway that prepares an (E)-isomer and a (Z)-isomer of ISATX247 such that the (E)-isomer and the (Z)-isomer are present in the mixture in a predetermined ratio, wherein the synthetic pathway comprises the steps of:
A method of preparing an isomeric mixture of cyclosporin A analogs modified at the 1-amino acid residue, the method comprising a synthetic pathway that prepares an (E)-isomer and a (Z)-isomer of ISATX247 such that the (E)-isomer and the (Z)-isomer are present in the mixture in a predetermined ratio, wherein the ratio of isomers in the mixture ranges from about 45 to 55 percent by weight of the (E)-isomer to about 55 to 45 percent by weight of the (Z)-isomer, based on the total weight of the mixture.
A method of preparing a predetermined isomeric mixture of cyclosporin A analogs modified at the 1-amino acid residue, the method comprising:
A method for the preparation of cyclosporin A aldehyde comprising the steps of:
A method of preparing an isomeric mixture of cyclosporin A analogs modified at the 1-amino acid residue, wherein the synthetic pathway comprises the steps of:
A method for the stereoselective synthesis of the E-isomer of ISATX247 comprising the steps of:
A method for the conversion of acetyl cyclosporin 1,3-diene to ISATX247 wherein the acetyl cyclosporin 1,3-diene is treated with a base selected from the group consisting of sodium hydroxide, sodium carbonate, potassium carbonate, sodium alkoxide, potassium alkoxide, and amine bases selected from the group consisting of NH3, hydroxylamine, hydrazine, and lower dialkylamines.
A method for the stereoselective synthesis of the Z-isomer of ISATX247 comprising the steps of:
Dependencies are inferred from the claim text.